SOFT TISSUE MATRIX CHARACTERIZATION USING STRETCHED EXPONENTIAL RELAXATION MODELING
20210244307 · 2021-08-12
Assignee
- The Regents Of The University Of Colorado, A Body Corporate (Denver, CO)
- Emory University (Atlanta, GA)
Inventors
Cpc classification
A61B5/055
HUMAN NECESSITIES
International classification
A61B5/055
HUMAN NECESSITIES
A61B5/00
HUMAN NECESSITIES
Abstract
A process for more sensitive characterization of tissue composition for generating a quantitative MRI (qMRI) map and corresponding delta analysis. Intervertebral disc degeneration (IVDD), resulting in the depletion of hydrophilic glycosaminoglycans (GAGs) located in the nucleus pulposus (NP), can lead to debilitating neck and back pain. Magnetic Resonance Imaging (MRI) is a promising means of IVD assessment due to the correlation between GAG content and MRI relaxation values. T1 and T2 relaxation data were obtained from healthy cervical IVDs, and relaxation data was modeled using both conventional and stretched exponential (SE) decays. Normalized histograms of the resultant quantitative MRI (qMRI) maps were fit with stable distributions. SE models fit relaxation behavior with lower error compared to monoexponential models, indicating anomalous relaxation behavior in healthy IVDs. SE model parameters T1 and T1 increased with IVD segment, while conventional monoexponential measures did not vary. The improved model fit and correlation between both SE T1 and T1 with IVD level suggests these parameters are more sensitive biomarkers for detection of GAG content variation.
Claims
1. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of: measuring a T1ρ.sub.SE relaxation time of glycosaminoglycan (GAG) in a disc of the subject using magnetic resonance imaging; comparing the measured T1ρ.sub.SE relaxation time to a baseline T1ρ.sub.SE relaxation time indicative of healthy tissue; measuring a α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in the disc of the subject using magnetic resonance imaging; comparing the determined α.sub.T1ρ relaxation time to a baseline α.sub.T1ρ relaxation time indicative of healthy tissue; and determining a decrease in the GAG content in the disc of the subject based on results of the comparing step for both the T1ρ.sub.SE relaxation time to a baseline T1ρ.sub.SE relaxation time and the α.sub.T1ρ relaxation time to a baseline α.sub.T1 relaxation time, wherein a decrease in the GAG content in the disc of a subject is indicative of IVDD in the subject.
2. The method according to claim 1 wherein T1ρ.sub.SE relaxation time of glycosaminoglycan (GAG) is measured in the nucleus pulposus of the subject using magnetic resonance imaging and wherein a decrease in the GAG content in the nucleus pulposus of a subject is indicative of IVDD in the subject.
3. The method according to claim 1 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
4. (canceled)
5. (canceled)
6. (canceled)
7. A method of monitoring progress of intervertebral disc degeneration (IVDD) in a subject comprising the steps of: measuring a baseline T1ρ.sub.SE relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of a subject using magnetic resonance imaging; measuring one or more additional T1ρ.sub.SE relaxation times; comparing at least one of the one or more additional T1ρ.sub.SE relaxation times measured to the baseline value of the T1ρ.sub.SE relaxation time; measuring a baseline α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in the NP of the subject using magnetic resonance imaging; measuring one or more additional α.sub.T1ρ relaxation times; comparing at least one of the one or more additional α.sub.T1ρ relaxation times measured to the baseline value of the α.sub.T1ρ relaxation time; and determining a decrease in the GAG content in the NP of the subject based on results of the comparing step for both the T1ρ.sub.SE relaxation time to a baseline T1ρ.sub.SE relaxation time and the α.sub.T1ρ relaxation time to a baseline α.sub.T1 relaxation time, wherein a decrease in the GAG content in the NP of a subject is indicative of continued IVDD in the subject.
8. (canceled)
9. A method of evaluating the effectiveness of an intervertebral disc degeneration (IVDD) treatment comprising the steps of: measuring a baseline T1ρ.sub.SE relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of a subject prior to or upon initiation of the treatment using magnetic resonance imaging; measuring a baseline α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of a subject prior to or upon initiation of the treatment using magnetic resonance imaging; initiating the treatment of the IVDD in the subject; measuring one or more additional T1ρ.sub.SE relaxation times after initiation of the treatment; comparing at least one of the one or more additional T1ρ.sub.SE relaxation times measured after initiation of the treatment to the baseline value of the T1ρ.sub.SE relaxation time; measuring one or more additional α.sub.T1ρ relaxation times after initiation of the treatment; comparing at least one of the one or more additional α.sub.T1ρ relaxation times measured after initiation of the treatment to the baseline value of the α.sub.T1ρ relaxation time; and determining a change in the GAG content in the NP of the subject based on results of the comparing step for both the T1ρ.sub.SE relaxation time to a baseline T1ρ.sub.SE relaxation time and the α.sub.T1ρ relaxation time to a baseline α.sub.T1 relaxation time, wherein an increase in GAG content is indicative of treatment effectiveness.
10. (canceled)
11. The method according to claim 9 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
12. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of: measuring a α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in a disc of the subject using magnetic resonance imaging; comparing the measured α.sub.T1ρ relaxation time to a baseline T1ρ.sub.SE relaxation time indicative of healthy tissue; and determining a decrease in the GAG content in the disc of the subject based on results of the comparing step, wherein a decrease in the GAG content in the disc of a subject is indicative of IVDD in the subject.
13. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of: measuring a α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of the subject using magnetic resonance imaging; comparing the determined α.sub.T1ρ relaxation time to a baseline α.sub.T1ρ relaxation time indicative of healthy tissue; and determining a decrease in the GAG content in the nucleus pulposus of the subject based on results of the comparing step, wherein a decrease in the GAG content in the NP of a subject is indicative of IVDD in the subject.
14. The method according to claim 13 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
15. A method of monitoring progress of intervertebral disc degeneration (IVDD) in a subject comprising the steps of: measuring a baseline α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of a subject using magnetic resonance imaging; measuring one or more additional α.sub.T1ρ relaxation times; comparing at least one of the one or more additional α.sub.T1ρ relaxation times measured to the baseline value of the α.sub.T1ρ relaxation time; and determining progress of intervertebral disc degeneration based on results of said comparing step.
16. A method of evaluating the effectiveness of an intervertebral disc degeneration (IVDD) treatment comprising the steps of: measuring a baseline α.sub.T1ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus of a subject prior to or upon initiation of the treatment using magnetic resonance imaging; initiating the treatment of the IVDD in the subject; measuring one or more additional α.sub.T1ρ relaxation times after initiation of the treatment; comparing at least one of the one or more additional α.sub.T1ρ relaxation times measured after initiation of the treatment to the baseline value of the α.sub.T1ρ relaxation time; and determining an effectiveness of the treatment based on results of the comparing step.
17. The method according to claim 16 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] For a fuller understanding of the invention, reference should be made to the following detailed description, taken in connection with the accompanying drawings, in which:
[0009]
[0010]
[0011]
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0022] Magnetic Resonance Imaging (MRI) is a promising tool for IVD assessment. GAG deficiencies are routinely assessed in the research setting using histology. However, it has long been a goal of medicine to detect early soft tissue degeneration in vivo. MRI is an ideal modality for early detection of IVDD in vivo due to its excellent noninvasive soft tissue contrast and routine clinical use. Furthermore, the ability of MRI to provide enhanced tissue characterization through quantitative relaxometry sets it apart as a diagnostic tool. In a comparable tissue, T.sub.2 relaxation analysis has been heavily utilized for in vivo cartilage assessment due to its sensitivity to collagen and water content. In contrast, while T.sub.2 values in the IVD have primarily been shown to be sensitive to water content, T.sub.1ρ values have been shown to be sensitive to GAG content.
[0023] While conventional relaxometry measures are helpful tools for detection of IVDD, monoexponential T.sub.2 and T.sub.1ρ values have shown limited specificity to individual matrix components. Anomalous relaxation has been observed in similar biological systems with non-monoexponential signal models showing additional tissue composition information. The stretched exponential (SE) function has been used widely for modeling biological and physical phenomenon. An SE function was used to model T.sub.2 relaxation data of bovine nasal cartilage, resulting in improved decay fitting and associating the stretching parameter α with GAG content in situ, suggesting an improved specificity to GAG content over conventional relaxation values. Therefore, a stretched exponential (SE) relaxometry model shows promise for improved IVDD composition and assessment.
[0024] Here we explore the use of the SE model to investigate healthy subject IVDs in vivo. Both conventional and SE models were applied to both T.sub.2 and T.sub.1ρ relaxation data. Ultimately, we show a wider dynamic range in SE T.sub.1ρ model parameters across disc level, suggesting greater sensitivity to known level-wise compositional variations between IVDs compared to conventional in vivo measures. These sensitivity increases could lead to improved imaging biomarkers, allowing for detection of subtle tissue composition changes such as those found in early IVDD.
Relaxation Models
[0025] The SE model for fitting transverse magnetization (T.sub.2) decay profiles has previously been derived [Reiter D A, Magin R L, Li W, Trujillo J J, Pilar Velasco M, Spencer R G. Anomalous T2 relaxation in normal and degraded cartilage. Magn. Reson. Med. 2016; 76:953-962 doi: 10.1002/mrm.25913; Magin R L, Li W, Pilar Velasco M, et al. Anomalous NMR relaxation in cartilage matrix components and native cartilage: fractional-order models. J. Magn. Reson. 2011; 210:184-91 doi: 10.1016/j.jmr.2011.03.006]. The conventional monoexponential T.sub.2 relaxation decay equation is written as:
M.sub.xy(t)=M.sub.0e.sup.−TE/T.sup.
Where M.sub.xy is the transverse magnetization, M.sub.0 is the initial magnetization, T.sub.2 is the calculated time constant, and TE is the echo time. The stretched exponential decay equation is written as:
M.sub.xy(t)=M.sub.0e.sup.−(TE/T.sup.
where the stretching parameter, α, allows for the modeling of broad continuous distributions of relaxation times suitable for capturing varying degrees of tissue microstructural complexity.
[0026] T.sub.2 relaxation times in complex tissues can depend on the selection of interpulse delays due to a variety of effects (e.g. diffusion through field inhomogeneities and spin-spin coupling). The influence of these effects, which result in varying degrees of spin dephasing, can be minimized by using a sufficiently short interpulse delay. In the limit of vanishing interpulse delay time relative to pulse length, magnetization is effectively locked in the rotating frame, and T.sub.2 relaxation approaches the spin-lattice relaxation time in the rotating frame, T.sub.1ρ. Through varying the application of the spin-lock pulse frequency, relaxation in the rotating frame can be measured over a wide range of frequencies below the Larmor frequency, permitting the observation of interactions between water and extracellular matrix molecules (i.e. exchange of protons between mobile matrix proteins and water). As T.sub.2 and T.sub.1ρ probe similar motional properties, and T.sub.2 has shown anomalous decay in IVDs, it is hypothesized that T.sub.1ρ may also exhibit anomalous decay. The conventional model for monoexponential T.sub.1ρ relaxation is written as:
M.sub.xy(TSL)=M.sub.0e.sup.−TSL/T.sup.
where TSL is the duration of the spin lock pulse. Similar to equation 2, the stretched exponential T.sub.1ρ relaxation model is written as:
M.sub.xy(TSL)=M.sub.0e.sup.−(TSL/T.sup.
[0027] Using equations 1-4, two different models (conventional and SE) for spin-spin and spin lattice relaxation in the rotating frame (T.sub.2 and T.sub.1ρ) yield 6 different model parameters to analyze: T.sub.2Mono, T.sub.2SE, α.sub.T2, T.sub.1ρMono, T.sub.1ρSE, and α.sub.T1ρ.
[0028] A graphical representation of the expected behavior of these models is shown in
EXAMPLE 1
Materials and Methods
Raw Data Acquisition and Processing
[0029] Cervical IVDs (C2C3-C6C7) were imaged in 15 healthy subjects (7/8 males/females; average age=24.7) using a 3T GE MRI scanner. A magnetization-prepared angle-modulated partitioned k-space spoiled gradient echo snapshots (MAPSS) T.sub.1ρ sequence was acquired with the following parameters: spin lock power: 500 Hz spin lock times: [1, 5, 20, 40, 60] ms [Li X, Wyatt C, Rivoire J, et al. Simultaneous acquisition of T1ρ and T2 quantification in knee cartilage: Repeatability and diurnal variation. J. Magn. Reson. Imaging 2014; 39:1287-1293 doi: 10.1002/jmri.24253]. A T.sub.2 sequence was also acquired (echo times: [6.78, 13.97, 21.15, 42.72] ms). Shared imaging sequence parameters were: FOV: 14 cm, matrix: 256×128, slice thickness: 4 mm, views per segment: 64, TR 1.2 s, number of slices: 26, ARC acceleration factor: 2, number of signal averages: 4.
[0030] The first spin lock time (TSL) for the T.sub.1ρ relaxation data was excluded from relaxation fitting due to the substantial increase in mean squared error it produced for all models compared with removal of other data (MSE). Pixel-by-pixel processing was chosen for analysis because of its relatively low noise compared to other techniques (
Region of Interest Analysis
[0031] Regions of interest (ROI) were manually segmented as binary masks containing the whole disc, AF, and NP using the T.sub.1ρ weighted image with the shortest TSL. To characterize differences in relaxation values of a tissue compartment, qMRI map histograms were created and normalized by the total number of pixels. To investigate potential differences between distributions of parameters between disc levels within a given tissue compartment, the histograms were fit with stable distributions with standard bounds (α=(0,2], β=[−1,1], γ=(0,∞), δ=(−∞,∞)) as the distributions were found to be non-normal (p>0.05). Analogous to the position of a normal distribution being represented by the distribution mean, the stable distribution position is represented by the δ value with α and β representing the distribution symmetry and skewness, respectively.
[0032] To compare level-wise differences in model parameters, the resultant δ values of each stable distribution (monoexponential, SE and α) were analyzed as a function of anatomical disc level. Each subject's IVD δ values were normalized by subtracting the lower fitting bound and then dividing by the full range of bounds and offsetting all IVDs for that subject by the C2C3 δ value:
δ.sub.IVD=(.sup.(δ.sup.
Statistics
[0033] Model deviations were characterized by comparing the MSE of both models using a one-way analysis of variance (ANOVA). Histogram normality was assessed using Shapiro-Wilks test. Absolute intradisc differences were determined using Kruskal-Wallis test. The correlation between δ values and IVD level was evaluated using a Spearman's rank correlation coefficient testing for monotonic relationships. Statistical significance was set at p<0.05.
EXAMPLE 2
Results
[0034] Single subject analysis shows level-wise increase in SE T.sub.2 and T.sub.1ρ model parameters moving caudally with IVD segment based on the δ values from the disc-wise distributions, but monoexponential models found no qualitative differences (
[0035] The population level (i) (n=15) T.sub.1ρ stable distribution analysis demonstrates a significant relationship between IVD level and SE model parameters (
[0036] The population level analysis of T.sub.2 data shows no significant correlation between parameters (T.sub.2Mono, T.sub.2SE, and α.sub.T2) and IVD segment. All distributions remain relatively constant (
[0037] This study was designed to evaluate the use of the SE fit in modeling healthy subject IVD MRI relaxometry in vivo. Both T.sub.2 and T.sub.1ρ relaxation was investigated. T.sub.1ρSE and α.sub.T1ρ significantly correlate with disc level. Both monoexponential models and the SE T.sub.2 model did not show any disc level dependence in these subjects.
[0038] The effectiveness of a stretched exponential model is dependent on two different phenomena: the presence of anomalous relaxation due to microscopic heterogeneity and the corresponding macroscopic change in decay time distributions. The monoexponential model was originally chosen to model bulk water which fit well due to the microscopic homogeneity of the sample [Bloch F. Nuclear Induction. Phys. Rev. 1946; 70:460-474 doi: 10.1103/Phys Rev. 70.460]. Therefore, when fitting both models to bulk water, the time constants for the monoexponential and SE models are expected to be equivalent (
[0039] The monoexponential model may not accurately represent the anomalous signal decay in complex materials. Therefore, the variation in monoexponential decay times may not reflect as large of a dynamic range as expected. The addition of the alpha parameter permits the SE decay model to capture this variation. The result of the SE model detecting the increase in heterogeneity is an increase in model dynamic range. Within a given tissue region consisting of multiple pixels, this increased relaxation parameter range can be characterized by a stable distribution detailing changes on the macroscopic level. Measured relaxometry distributions of T.sub.1ρSE and α.sub.T1ρ suggest higher sensitivity to the expected level-dependent IVD composition differences than T.sub.1ρMono (
[0040] The SE model has a significantly lower MSE (p<0.01) suggesting a non-monoexponential model is a more appropriate decay fit. Furthermore, the SE model can recover a monoexponential decay with an α fit value of 1 (
[0041] Inspection of the stable distributions from a single subject highlights differences in model fits (
[0042] The population level T.sub.1ρ results are consistent with the hypothesis that δ values correlate with expected whole disc GAG content (
[0043] The T.sub.2 parameters show no significant correlation to IVD level (
[0044] A stretched exponential model of T.sub.1ρ IVD relaxation yields more sensitive insights into IVD health. Current literature suggests a strong correlation between absolute GAG content, IVD health, and monoexponential T.sub.1ρ IVD relaxation. However, these in vivo approaches are typically at the population level (e.g. with cohorts greater than 15 participants (32-34)) and/or not IVD location specific (18), yielding limited utility at the individual patient level. A patient level correlation between relative IVD location and T.sub.1ρ values has never been demonstrated. The data presented here demonstrates this correlation thus indicating a before unknown measure of sensitivity which could prove useful in detecting finer IVD compositional changes, such as those present in early IVDD.
[0045] We observed no obvious level-wise variation in SE T2 model parameters in our healthy population. This may be due to the more limited acquisition parameters we used for in vivo imaging (e.g. echo times, signal quality, etc). Further studies can compare structural properties in model tissue systems with these relaxation model parameters to investigate their relationship to IVD function. Despite removing the first TSL, reliable exponential decay fits were achieved highlighting the reliability of the collected data. The overall dataset SNR is low, causing minor data exclusion. Disease oriented studies could investigate the efficacy of the SE fit for IVDD preclinical (animal) and clinical models in vivo.
[0046] The conventional monoexponential T.sub.1ρ decay model has been shown to correlate with GAG content. Additionally, T.sub.1ρ NP values decrease with disc degeneration. However, the conventional fit may provide a limited representation of the relaxation features available as they relate to important matrix-water interactions limiting standard relaxometry measures sensitivity to characterize IVD tissue status. Using a stretched exponential model with the addition of the α term will lead to improved sensitivity and possibly provide earlier detection of IVDD (
[0047] One advantage of knowing IVD status would be increased sensitivity to IVD composition. When monitoring IVD health of a patient, a physician would have a more accurate understanding of the current situation. For instance, if the patient was bordering on having spinal fusion surgery, something that is often put off until necessary, it would help the physician make the right decision and feel more confident in their approach to treating the patient.
[0048] It will be seen that the advantages set forth above, and those made apparent from the foregoing description, are efficiently attained and since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
[0049] It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween. Now that the invention has been described.